AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Business

AbbVie Invests $100 Million in Morphic Therapeutics to Develop Integrin Inhibitors for Fibrotic Diseases

Weeks after Waltham, Mass.-based Morphic Therapeutic secured $80 million in Series B financing that was supported in part by AbbVie Ventures, the company struck a deal with the pharma giant to collaborate on the development of therapies for fibrosis-related indications.

October 18, 2018

2 min read

Alex Keown

Business

The Perils and Promise of Partnerships Between Biopharma and Data Companies

Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.

October 16, 2018

4 min read

Mark Terry

Policy

AbbVie’s Humira is the world’s best-selling drug that generated more than $18 billion for the Illinois-based company last year. This week though, the company will begin to see challenges to Humira in Europe from biosimilars developed by Amgen and Novartis, as well as others.

October 16, 2018

2 min read

Alex Keown

Business

Nobel Prizes Underscore Benefits of Research, but Also Highlight ‘Worst Instincts’ of Industry: Report

In a report, Bloomberg said that pharma’s “efforts to maximize (financial) gains” has led to the coloring of R&D decisions and creating barriers to the entry of competing medications that can add costs to the health care system.

October 8, 2018

2 min read

Alex Keown

Business

Frances Arnold 5th Woman to Win Nobel Prize in Chemistry, Joining Madame Curie and Her Daughter

The 2018 Nobel Prize in chemistry was awarded to Frances H. Arnold, George P. Smith and Gregory P. Winter for research in utilizing evolutionary principles to create proteins.

October 3, 2018

2 min read

Mark Terry

Business

Momenta Slashes Workforce and Leadership Following Strategic Review

Despite winning regulatory approval for a copycat version of Copaxone earlier this year, Cambridge, Mass.-based Momenta Pharmaceuticals has completed a strategic review that includes slashing its staff by 50 percent as the company focuses its resources on two biosimilar candidates in its pipeline.

October 2, 2018

2 min read

Alex Keown

Deals

Roche Focuses on T Regulatory Cells in $758 Million Acquisition of Tusk Therapeutics

Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).

September 28, 2018

3 min read

Mark Terry

FDA

Verastem Gets FDA Approval for Leukemia Drug, Will Make It Immediately Available to Patients

Shares of Verastem closed out Monday trading on a positive note and continues to climb in the premarket following the greenlight for leukemia drug Copiktra, an inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma.

September 25, 2018

3 min read

Alex Keown

Policy

Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services

A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service.

September 21, 2018

3 min read

Alex Keown

JOBS